ALG-093940 / Aligos Therap - LARVOL DELTA

Preclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor for the treatment of chronic hepatitis B infection and liver cancer (EASL 2026) - No abstract available

Preclinical • Hepatitis B • Hepatology • Infectious Disease • Liver Cancer • Oncology • Solid Tumor

Preclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor targeting PD-L1 dimerization, internalization and degradation (AACR 2026) - "ALG-093940 showed comparable T-cell activation potency to INCB086550 an orally dosed small molecule PD-L1 inhibitor which demonstrated clinical responses in a phase I study. ALG-093940, an orally available small molecule, is a potent PD-1/PD-L1 inhibitor targeting PD-L1 dimerization, internalization and degradation. ALG-093940 demonstrated excellent efficacy and safety, warranting further evaluation as a potential clinical candidate for the treatment of cancer."

Preclinical • Oncology • CD8